BASEL, Switzerland, December 5, 2013/African Press Organization (APO)/ —
• Africa’s healthcare challenges are compounded as it begins to face a dual disease burden as non-communicable diseases rise
• In addition to existing corporate responsibility efforts such as its Malaria Initiative, Novartis is implementing innovative commercial models, utilizing new technologies and increasing healthcare education and training
• African countries seen as the next set of fast growing markets as middle class projected to grow substantially
Today, Novartis senior executives gather in Basel, Switzerland for the first-ever Novartis Africa Day (http://www.novartis.com), to review the company’s innovative work in Africa, including growing commercial activity, novel approaches to expand access to high-quality, affordable medicines, local talent development and the company’s Malaria Initiative.
Download the infographic: http://www.apo-mail.org/131204.pdf
Logo Novartis Africa Day: http://www.photos.apo-opa.com/plog-content/images/apo/logos/nad.png
Logo Novartis: http://www.photos.apo-opa.com/plog-content/images/apo/logos/novartis.jpg
“Novartis is taking an outcomes approach, looking beyond therapeutic solutions to a focus on new technologies, new commercial models, education and training,” says Joseph Jimenez, Chief Executive Officer of Novartis, who will open the event. “As the continent increasingly grapples with the dual healthcare burden of communicable and non-communicable diseases, we believe we can make a significant difference in improving lives as the demand for healthcare rises.”
Africa faces immense challenges in its efforts to provide adequate healthcare to its people. The continent is home to one-seventh of the world’s population, shoulders one-quarter of the global disease burden, but it has only two percent of the world’s doctors and less than one percent of global health expenditure (1). Life expectancy is 15 years less than the global average (2). Africa is also at a turning point as it begins to be challenged by a dual disease burden – both communicable diseases that have historically plagued the continent, such as malaria, and non-communicable diseases that are on the rise due to lifestyle changes, such as diabetes. Low levels of disease awareness, declining infrastructure and poor distribution channels further compound Africa’s problems.
Novartis employs a range of activities on the African continent with the aim of becoming the leading healthcare company in Africa. Programs to be discussed at today’s event include Sandoz Health Shops in Zambia, the Novartis Malaria Initiative (http://www.malaria.novartis.com/malaria-initiative/index.shtml) and SMS for Life (http://www.malaria.novartis.com/innovation/sms-for-life). Sandoz Health Shops have the potential to reach more than 2.5 million patients over the next four years. The Novartis Malaria Initiative has provided more than 600 million antimalarial treatments, without profit, to more than 60 malaria-endemic countries. In addition, SMS for Life has reduced wait times and stock-outs for antimalarial medicines from three months to a few days and from 79% to less than 26% in three districts in Tanzania.
To learn more about Novartis’ continued efforts in Africa, please visit http://www.novartis.com.
Distributed by APO (African Press Organization) on behalf of Novartis.
1. WHO. “Global Health Observatory”.
2. WHO. “Global Health Observatory”.
This press release contains expressed or implied forward-looking statements, including statements that can be identified by terminology such as “aim,” “potential,” or similar expressions, or by express or implied discussions regarding potential future revenues from sales in Africa. Such forward-looking statements reflect the current views of the Group regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results expressed or implied by such statements. There can be no guarantee that Novartis’ efforts in Africa will be commercially successful in the future. In particular, management’s expectations could be affected by, among other things, risks and factors referred to in the Risk Factors section of Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update it in the future.
Novartis (NVS) (http://www.novartis.com) provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2012, the Group achieved net sales of USD 56.7 billion, while R&D throughout the Group amounted to approximately USD 9.3 billion (USD 9.1 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 133,000 full-time equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.novartis.com.
Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis.
Novartis Media Relations
Central media line : +41 61 324 2200
Novartis Global Media Relations
+41 61 324 7999 (direct)
+41 79 593 4202 (mobile)
Novartis Global Media Relations
+41 61 324 7973 (direct)
+41 79 523 0198 (mobile)
For Novartis multimedia content, please visit http://www.thenewsmarket.com/Novartis
For questions about the site or required registration, please contact: firstname.lastname@example.org.
Novartis Investor Relations
Central phone: +41 61 324 7944
Samir Shah +41 61 324 7944
Pierre-Michel Bringer +41 61 324 1065
Thomas Hungerbuehler +41 61 324 8425
Isabella Zinck +41 61 324 7188
Stephen Rubino +1 862 778 8301
Jill Pozarek +1 212 830 2445
Susan Donofrio +1 862 778 9257